ABSTRACT
The clinical syndrome of mild cognitive impairment (MCI) has been associated with increased risk of Alzheimer disease (AD). 1 Patients with amnestic MCI 2 convert to AD at an annual rate of about 16% per year, whereas the conversion rate may be as high as 41% after 1 year and 64% after 2 years. Some patients with diagnosis of MCI, however, may never convert to AD or even return to normal. 3 Thus, in view of the high variance of clinical progression of MCI, markers related to the neuropathology of AD are needed to accurately predict the conversion of MCI to AD. Especially in light of new therapeutic developments that may delay or arrest the progression of AD, the accurate predementia prediction of AD is pivotal in order to allow for early secondary prevention.
P-tau measured in CSF has been proposed as a core feasible candidate marker for the early detection of AD. [5] [6] [7] The rationale for p-tau as a predictor is that p-tau is a major component of pre-tangle paired helical filaments and mature neurofibrillary tangles that are present within the brain even before the onset of AD, [8] [9] [10] where p-tau may be sequestered into the extracellular CSF. 11 CSF levels of p-tau as assessed from CSF have been extensively studied in over 700 patients with AD and 300 controls in several independent studies, with an average sensitivity of 78% and specificity of 92%. [12] [13] [14] Longitudinal studies in subjects with MCI showed promising results for p-tau phosphorylated at different epitopes including threonine 181, threonine 231, and serine 199 as predictors of cognitive decline and conversion to AD. [15] [16] [17] [18] [19] [20] Recently, it has been criticized that a pivotal requirement for the evaluation of clinical utility of a biomarker candidate, i.e., potential site-to-site differences of predictive accuracy, has not been assessed due to lack of an established cutoff value of p-tau. 17 Here we report a multicenter study examining a relatively large sample regarding the accuracy of p-tau 231 for the prediction of the conversion from MCI to AD within a clinically relevant observation interval of 1.5 years on average, using a fixed quantitative criterion of p-tau 231 .
METHODS Subjects. A total of 145 patients including 88
patients with amnestic MCI and 57 healthy controls were recruited at four international clinical research centers including the VU University Medical Centre, Amsterdam, the Netherlands, Pitea River Hospital, Pitea, Sweden, Department of Psychiatry, University of Heidelberg, and Alzheimer Memorial Center, Department of Psychiatry, LudwigMaximilian University, Munich, Germany. All patients with MCI and healthy controls were retrospectively included in the study to control for the number of subjects in each group including MCI converters and MCI nonconverters. Subjects were quasi-randomly selected based on the criteria that at least one CSF sample at time of diagnosis and at least one clinical follow-up with a time interval of 1 to 3 years must be present. Patients were assessed between 2000 and 2004. The descriptive statistics on gender, age, Mini-Mental State Examination (MMSE), and duration of follow-up interval of the clinical assessments are displayed in table 1.
Diagnosis of AD was made according to the National Institute of Neurological and Communicative Disorders and Stroke-AD and Related Disorder Association criteria. 21 For determining conversion from MCI to AD, subjects had to show a CDR Ն1 and functional impairment assessed on the basis of the Bayer activities of daily living scale.
For the diagnosis of MCI, patients fulfilled the following criteria: 1) the person was neither normal nor had dementia; 2) there was evidence of cognitive deterioration both objectively and subjectively; and 3) activities of daily living were preserved and complex instrumental functions were either intact or minimally impaired. 22, 23 For the single-domain am- nestic type of MCI, the diagnostic criteria included a performance in memory performance that lay at least one SD below the age-adjusted norm on at least one of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) memory subtests, where multidomain amnestic MCI was diagnosed if a score of one SD below the norm in at least one other cognitive domain was present. At the remaining center (Heidelberg), the patients were diagnosed with aging-associated cognitive decline as described previously 24, 25 that corresponds to the definition of multidomain amnestic or non-amnestic type of MCI. 23 Briefly, diagnostic criteria of aging-associated cognitive decline include 1) subjective cognitive decline, 2) objective cognitive impairment in at least one of five cognitive domains including learning and memory, attention/concentration, abstract thinking, language, and visuospatial functioning (at least 1 SD below the norm), and 3) absence of dementia or psychiatric disorder, cerebral damage, or physical disease that may account for the cognitive deficits. 24 The healthy controls performed normally on the CERAD neuropsychological test battery 26 or MMSE and showed no history of axis 1 and 2 disorder according to the DSM-IV criteria. 27 The healthy controls had no history of cerebrovascular disease, diabetes mellitus, thyroid dysfunction, liver or kidney disease, or uncontrolled hypertension. Routine assessment involved physical, neurologic, and psychiatric examination, neuropsychological assessment using the CERAD battery, 19 chest X-ray, ECG, EEG, cranial MRI, and routine laboratory tests (complete blood count, sedimentation rate, electrolytes, glucose, urea, creatinine, liverassociated enzymes, cholesterol, high density lipoprotein, triglycerides, antinuclear antibodies, rheumatoid factor, Venereal Disease Research Laboratory, HIV, serum B12, folate, thyroid function tests, and urine analysis). To assess whether the MCI subjects converted to AD, diagnostic assessment as described above was repeated for a second time. The duration of the follow-up interval for each center is displayed in table 1. The diagnostics were done blinded previous to the analysis of p-tau 231 . The study was approved by the local review boards or local ethics committees of each participating center.
ApoE genotype was available in a total of 75 MCI subjects, including 34 MCI converters and 41 MCI nonconverters. ApoE genotype was divided into binary groups, including subjects who either carried at least one ApoE 4 allele (ApoE 4 carriers) vs those who showed no 4 allele (ApoE 4 noncarriers). The distribution of the binary ApoE 4 carrier status per center and diagnostic group is shown in table 1. Specifically, the ApoE genotype distribution for the MCI converters was ApoE 2/3: n ϭ 0, 2/3: n ϭ 2, 3/3: n ϭ 8, 3/4: n ϭ 15, and 4/4: n ϭ 9, and for MCI nonconverters ApoE 2/3: n ϭ 2, 2/3: n ϭ 3, 3/3: n ϭ 19, 3/4: n ϭ 13, and 4/4: n ϭ 4.
ELISA-based analysis of p-tau 231 . CSF was obtained by lumbar puncture within a time interval of 2 weeks after diagnostic assessment. Levels of p-tau 231 in CSF were measured using a sandwich ELISA developed by Applied NeuroSolutions, Inc. (Vernon Hills, IL) as previously described, 28 with the exception that a synthetic peptide was used as the standard. The ELISA-based analysis was done blinded to the diagnostic status by an expert (R.Z.) who has extensive experience and publication record on such methods. Briefly, capture antibodies that recognize tau (CP27 and Tau-1) are immobilized in microtiter wells via a goat anti-mouse Fc antibody (CP27 reacts with tau backbone in the region of amino acids 130 -150 using full length tau [441 amino acids] for the numbering scheme. Tau1 reacts with tau in the region around amino acids 196 -205 when none of those residues are phosphorylated). The sandwich antibody, CP9, is specific for phospho-threonine 231. The sandwich antibody is detected using a biotinylated goat F(ab=) 2 anti-mouse IgM specific antibody and horseradish peroxidase-conjugated streptavidin.
For the standard curve, various concentrations of a synthetic peptide corresponding to amino acid numbers 185-235 of human tau were used. The threonine residue corresponding to threonine 231 in human tau contains a phosphate group. Lumbar puncture was associated with headache in less than 5% of cases; if a headache occurred subjects were treated with appropriate analgesics. Headaches subsided within a period of no longer than 2 days.
Statistics.
For cross-sectional analysis of the differences in p-tau 231 levels among the MCI converters, MCI nonconverters, and healthy controls, an analysis of covariance (AN-COVA) with group as the independent variable and age and gender as covariates was conducted. Separate ANCOVAs comparing levels of p-tau 231 between centers within each subgroup of patients with MCI (i.e., MCI converters and MCI nonconverters) were conducted, using MMSE, age, and gender as covariates. To examine whether differences of levels of p-tau 231 exist between centers within MCI converters and MCI nonconverters, separate ANCOVAs with center and gender as fixed factors and age and MMSE as covariates were computed for each MCI subgroup. To assess the predictive value of p-tau 231 for conversion from MCI to AD, a Cox proportional hazards model was used on the basis of the data obtained from the patients with MCI stratified according to center. The main outcome variable was conversion to AD, with p-tau 231 , age, gender, MMSE, and ApoE genotype entered as predictors, and the follow-up interval as the time variable. To cross-validate the classification of the conversion status on the basis of p-tau 231 between centers, first the optimal classification criterion was determined on the basis of a training set. To this end, the data of the center in Sweden were used since this center provided the largest sample size that was equally split between MCI converters and MCI nonconverters (n ϭ 19), thus allowing for the best statistical validity. A receiver operating characteristic (ROC) curve for the prediction of the conversion status was created, using p-tau 231 as the predictor. On the basis of the specificity and sensitivity determined for each coordinate of the ROC curve, the level of p-tau 231 that showed a sensitivity of larger than 80% combined with a maximal specificity was chosen. The cutoff value thus determined was subsequently applied to the data sets of each of the other centers to predict the conversion, where specificity and sensitivity was obtained.
To gain further insight into the variability of predictive accuracy independent of sample size, we used bootstrapping. Specifically, we computed 1,000 iterations of N-1 resampling with replacement, drawn from the sample of 50 subjects with MCI across the three centers Amsterdam, Heidelberg, and Munich. The arithmetic mean and 95% CI of the sensitivity, specificity, and classification accuracy for the fixed cutoff point were recorded, using an algorithm written in Matlab 7.2 (The MathWorks Inc., Natick, MA).
To determine the optimal cutoff value for each center, the ROC analysis was run for each center separately and the cutoff value yielding a sensitivity of Ͼ80% along with the maximal specificity was chosen. Classification accuracy defined as the percentage of correctly classified cases was calculated for each ROC analysis. Variability of cutoff values was further assessed in bootstrapped samples of n ϭ 20 each of MCI-MCI and MCI-AD groups. Out of the total of subjects across all centers (n ϭ 88), subjects were randomly sampled for 1,000 iterations. The optimal cutoff point defined in terms of reaching a sensitivity of at least 80% while maximizing the specificity was recorded, using a code written in Matlab 7.2. The mean age across centers was 62.93 years (95% CI) for the control group, 88.11 (SD ϭ 8.07) for MCI nonconverters, and 73.73 (SD ϭ 6.4) for MCI converters. The group difference in age was significant (p Ͻ 0.001). A regression analysis with age and diagnostic group showed that an increase of age was associated with an increase in levels of p-tau 231 independently of diagnostic group (p ϭ 0.01).
RESULTS
Results of an ANCOVA examining center differences in p-tau 231 at baseline showed neither in MCI converters (p ϭ 0.16) nor MCI nonconverters (p ϭ 0.37) significant differences between centers, suggesting that the levels of p-tau 231 were comparable across centers for each patient group.
Prediction of conversion from MCI to AD based
upon p-tau 231 levels. Results of the Cox proportional hazards analysis showed that p-tau 231 levels were a significant predictor of the conversion Figure 1 Mean levels of p-tau 231 for healthy controls, mild cognitive impairment (MCI) nonconverters, and MCI converters at baseline
Figure 2
Cumulative hazard of conversion from mild cognitive impairment to Alzheimer disease as a function of follow-up interval for each center
Error bars indicate one unit of SD. from MCI to AD (B ϭ 0.026, SE ϭ 0.002, p ϭ 0.001, figure 2 ). None of the other covariates entered including age, MMSE, and gender were a significant predictor of conversion. When ApoE was taken as a covariate into the model, p-tau 231 levels remained in the model. To assess the specificity and sensitivity of a fixed criterion of p-tau 231 levels to discriminate between MCI converters and nonconverters we first determined the optimal cutoff point within the sample at a center from Sweden (i.e., training set) on the basis of the ROC curve (see figure 3 for ROC curves for each center). At a cutoff point of 27.32 pg/mL, the sensitivity was 84.21% while the specificity was 63.16%. When applying the cutoff value of 27.32 pg/mL to classify the conversion status in each of the other centers samples, the sensitivity ranged between 66.67 and 100% and the specificity between 66.67 and 77.78% (table  2) . The bootstrapped mean sensitivity was 87.47% (95% CI ϭ 87.41 and 87.63%), specificity was 73.00% (95% CI ϭ 72.92 and 73.08%), and classification accuracy was 79.95 (95% CI ϭ 79.90 to 80.00%).
When using cutoff point of p-tau 231 determined for each center separately the sensitivity ranged between 84 and 100% and the specificity between 63 and 78% (table 3). The mean percentage of correctly classified cases averaged across centers was 77.51% (SD ϭ 5.31) for the fixed cutoff and 79.91% (SD ϭ 4.16) for the center-specific cutoffs (tables 2 and 3).
The bootstrapped mean cutoff point was 32.18 pg/mL p-tau (95% CI ϭ 31.93 to 32.43%), yielding a mean sensitivity of 81.09% (95% CI ϭ 80.94 to 81.24), a specificity of 79.81% (95% CI ϭ 79.19 to 80.43%), and classification accuracy of 80.45% (95% CI ϭ 80.24 to 80.76%).
DISCUSSION
The aim of the present study was to assess the utility of a standardized quantitative criterion of p-tau 231 for the prediction of the conversion from MCI to AD when assessed across multiple clinical sites. The major finding of the current study was that the accuracy of classification of MCI converters vs MCI nonconverters was comparable for an a priori determined fixed cutoff value vs center-specific post hoc determined cutoff values of p-tau 231 . Only at one center (Munich), the classification accuracy was raised when applying a post hoc optimized rather than a priori determined cutoff value, which yielded, however, only a single additional case that was correctly classified (out of a total of 88 patients with MCI). The bootstrapped results support this observation, showing that the a priori defined cutoff value, i.e., 27.31 pg/mL, yields a classification accuracy at least as high as that observed in the Swedish reference sample. The present results are pertinent to the clinical utility of p-tau for the prediction of the conversion from MCI to AD especially because a relatively short time interval which is clinically relevant was used.
Regardless of whether a post hoc determined cutoff value or a standard value was used for the prediction of AD, the predictive accuracy of p-tau 231 varied to some extent between centers. Methodologic differences in the p-tau analysis between centers cannot explain the variance in predictive accuracy since the p-tau concentration was centrally analyzed using the same assay. A potential explanation for the multicenter variance in the predictive accuracy is that the stage of disease progression of the patients with MCI, i.e., the severity of cognitive deficits and underlying neuropathology, may have varied between centers, potentially entailing differences in the expected time of conversion. The relatively constrained but clinically meaningful time win- Figure 3 ROC curves for the prediction of conversion from mild cognitive impairment to Alzheimer disease based upon levels of p-tau 231 for each center Cutoff level was determined at the training set (center of Göteborg).
The dow of about 1.5 years and the binary prediction model based on p-tau 231 cutoff may fail to capture such larger differences in the temporal expectation of the progression of MCI. MMSE differences between centers suggest that the level of severity of cognitive deficits in MCI may have varied between centers. Levels of p-tau, however, were significantly different between centers neither in the MCI nonconverters nor in the MCI converters, suggesting that the degree of tau-related pathology as assessed by p-tau in CSF was comparable across centers.
Note that the center-wise analysis yielded relatively small sample size per center, which may have introduced variability. To assess the variability of classification accuracy within the multicenter samples further, we used bootstrapping. The bootstrapped results on classification accuracy were somewhat less variable when compared to the center-wise analysis, possibly due to less variability in sample size. It should be taken into consideration that the current leave-one-out bootstrapping analyses may provide a good estimate of variability of classification accuracy across centers, but less so in terms of centerspecific variance due to pooling of the data.
In a similar vein, the variability of post hoc defined cutoff values was reduced when bootstrapping was used rather than center-wise analysis. In the latter case, variability was lower even when half of the total sample per iteration was sampled, suggesting that the center-specific analyses may have yielded a rather liberal estimate of variability within the multicenter sample.
A way to improve the clinically important short-term prediction of the conversion from MCI to AD may be a multidimensional prediction model combining levels of p-tau 231 with other potential biomarkers. Results from recent studies showed that total tau and beta-amyloid (A␤ 42 ) measured in CSF may yield predictive information for the progression of MCI and conversion to AD. 29 Furthermore, the combination of p-tau with such markers may significantly enhance the predictive accuracy of p-tau, reaching a sensitivity as high as 95% along with a specificity of 83%. 18 Thus a combination of different CSF-derived markers may raise the accuracy of the prediction of AD to clinically relevant levels, i.e., sensitivity and specificity Ͼ 80%. 6, 7, 23 Such a predictive model, however, still awaits cross-validation. Other potential markers to aid in a multidimensional model of risk assessment could be MRIbased indices such as the hippocampus volume or regional patterns of cortical atropy, [30] [31] [32] glucose metabolism measured by PET, 33, 34 and other candidates derived from blood and CSF. 12, 35 For ApoE genotype, which is a major risk factor of AD, the present results showed that ApoE 4 frequency was significantly increased in those patients with MCI who converted to AD. However, p-tau 231 appears to be the stronger predictor of conversion from MCI to AD, with ApoE genotype not contributing significantly to the prediction of conversion when p-tau levels are accounted for. These results are consistent with some previous studies, 29 although others have found an association between ApoE genotype, in addition to p-tau, and conversion from MCI to AD. 20 Differences between the findings may be explained in terms of the duration of follow-up interval, as the study in which a combined effect of both p-tau and ApoE genotype on conversion to AD was detected used an extended follow-up interval over 3.5 years 20 compared to about 8 months in the other study with negative findings. 29 P-tau, which was shown to correlate with the rate of hippocampal atrophy, 36 may act as an indicator of the disease acuity, and thus be a more potent predictor within a short-term interval such as chosen in the current study. ApoE genotype may add significantly to the prediction of MCI only at longer time intervals.
The increased levels of p-tau 231 in the MCI converters may be indicative of presence of AD cerebral pathology which may herald the clinical manifestation of AD. 37 We hypothesized that MCI converters have abnormally increased levels of p-tau 231 but not the MCI nonconverters when compared to normal controls, arguing that MCI converters but not MCI nonconverters bear ADspecific pathology. Indeed, the current result pattern appears to support this hypothesis in that p-tau levels were significantly increased only in the MCI converters at baseline, whereas MCI nonconverters showed no significant difference compared to healthy controls. A potential caveat is that age was a potential confounding variable Table 3 Optimal cutoff levels and associated sensitivity and specificity for each center in the cross-sectional analysis. Age differed significantly between groups. However, for the group comparison, age was included as covariate, showing that p-tau levels remained different between MCI converters and the remaining two groups. The current results are also consistent with previous findings of such a result pattern, i.e., MCI converter Ͼ MCI nonconverter ϭ controls, 18 supporting the current findings.
The current sample of MCI subjects included both the amnestic type of MCI at three centers 2 and the broader syndrome of AACD 24 consisting of both the amnestic and non-amnestic subgroups of MCI 23 at the fourth center. The predictive accuracy seemed to be similar in the AACD patients when compared to patients with amnestic type MCI, as the percentage of correctly classified patients did not seem to correlate with the type of diagnosis. Future studies including different subtypes of MCI subjects, however, are needed to examine whether the predictive accuracy of p-tau 231 and other potential biomarkers can be generalized across different subgroups of MCI.
As a potential caveat of the interpretation of results of the present study it should be mentioned that MMSE measured at baseline was lower and the follow-up interval longer in MCI converters. In our Cox regression analysis on p-tau, however, we addressed the potential influence of these variables including baseline MMSE as a covariate. Cox regression analysis corrects differences in follow-up interval by taking into account potential censoring effects. Our results showed that CSF levels of p-tau were a significant predictor of conversion to AD, suggesting that independent of baseline MMSE status, p-tau 231 is a significant predictor of disease progression in MCI. In addition, MMSE at baseline was not a significant predictor of disease progression in the current MCI sample. With regard to levels of p-tau, lower MMSE points were not associated with increased p-tau values in the patients with MCI as tested in a Pearson moment correlation (r ϭ 0.18, p ϭ 0.10), suggesting that the increased levels of p-tau 231 in MCI converters may not be explained by differences in MMSE.
Another caveat of the present study is that the MMSE was rather low in the some of the patients with MCI so that one may argue that some patients with MCI may have had already AD. Although the MMSE score was taken into account for the diagnosis, full cognitive assessment was based on a comprehensive battery of neuropsychological tests, including tests on semantic and episodic memory, visuospatial abilities, attention, and executive functions, among others. Final diagnosis was based on the physical, neurologic, and neuropsychological information. On the basis of such information, dementia was not diagnosed in any of the subjects at baseline. We used standard criteria for the diagnosis of MCI to yield a decision criterion as may be applied in clinical routine diagnostics. Using such diagnostics criterion as the reference, the results of the present study suggest that p-tau 231 , although not sufficient as the only predictor, may contribute to the prediction of disease progression in MCI.
